Editorials

Diabetes and lipid lowering: where are we?

BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7550.1103 (Published 11 May 2006) Cite this as: BMJ 2006;332:1103
  1. John P D Reckless (mpsjpdr@bath.ac.uk), consultant endocrinologist
  1. Royal United Hospital, Bath BA1 3NG

    We're now sure that statins cut cardiovascular risks in type 2 diabetes

    Premature morbidity and mortality is substantially due to cardiovascular disease, with tobacco use, hypertension, and abnormal lipids being the main modifiable causal factors. Glycaemia is directly related to cardiovascular risk,1 and in people with diabetes the risk of cardiovascular disease approaches that in non-diabetic people with previous myocardial infarction.2 3

    Because most people with type 2 diabetes have an absolute risk of cardiovascular disease of 20% or more over 10 years, guidelines suggest active intervention to reduce risk factors in patients with diabetes, including statin therapy to reduce the serum concentration of low density lipoprotein cholesterol (LDL-C) to < 2 mmol/l.3 In this week's BMJ Costa and colleagues report a meta-analysis of trials of lipid lowering drug therapy for primary and secondary coronary heart disease prevention in patients with and without diabetes.4

    Review by the National Institute for Health and Clinical Excellence (NICE) of the role of statins in preventing cardiovascular disease has endorsed the routine use of statins in people with an absolute risk of 3 20% over 10 years as effective and cost effective …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe